Candid Therapeutics

Candid Therapeutics is a San Diego, California clinical-stage biotechnology company developing T-cell engager (TCE) antibody therapies for autoimmune and inflammatory diseases. Launched publicly in September 2024 with a $370 million Series A financing and assembled by acquiring Vignette Bio and TRC 2004, Candid in-licenses differentiated bispecific TCE assets and advances them through US clinical development. Its approach redirects T-cells to selectively deplete autoreactive B-cells, aiming for deeper and more durable depletion than conventional antibody therapy without the manufacturing burden of cell therapy. Its lead investigational asset, cizutamig, is a BCMA x CD3 bispecific antibody. UCB completed its acquisition of Candid Therapeutics on 17 June 2026 for up to $2.2 billion ($2.0 billion upfront plus up to $200 million in milestones), and the company now operates as part of UCB. Candid Therapeutics publishes no public API, developer portal, SDK, or machine-readable specification.

Candid Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.

🌐 Visit website 📡 Source on GitHub
9.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesImmunologyAutoimmune DiseaseClinical TrialsTherapeuticsAntibodiesDrug Development

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1
Composite quality — 9.5/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.9 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/candid-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Candid Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService

Company 2

The organization behind the API

Website
Website
 About
About

Other 4

Properties that don't map to a standard resource type

Accessibility
Accessibility
 BoardOfDirectors
BoardOfDirectors
 SecondaryMarket
SecondaryMarket
 ParentCompany
ParentCompany

Source (apis.yml)

apis.yml Raw ↑ 
aid: candid-therapeutics
name: Candid Therapeutics
description: Candid Therapeutics is a San Diego, California clinical-stage biotechnology company developing T-cell engager
  (TCE) antibody therapies for autoimmune and inflammatory diseases. Launched publicly in September 2024 with a $370 million
  Series A financing and assembled by acquiring Vignette Bio and TRC 2004, Candid in-licenses differentiated bispecific TCE
  assets and advances them through US clinical development. Its approach redirects T-cells to selectively deplete autoreactive
  B-cells, aiming for deeper and more durable depletion than conventional antibody therapy without the manufacturing burden
  of cell therapy. Its lead investigational asset, cizutamig, is a BCMA x CD3 bispecific antibody. UCB completed its acquisition
  of Candid Therapeutics on 17 June 2026 for up to $2.2 billion ($2.0 billion upfront plus up to $200 million in milestones),
  and the company now operates as part of UCB. Candid Therapeutics publishes no public API, developer portal, SDK, or machine-readable
  specification.
url: https://raw.githubusercontent.com/api-evangelist/candid-therapeutics/refs/heads/main/apis.yml
image: https://www.candidrx.com/wp-content/uploads/2024/08/candid-logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Autoimmune Disease
- Clinical Trials
- Therapeutics
- Antibodies
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/candid-therapeutics-domain-security.yml
- type: Website
  url: https://www.candidrx.com/
- type: About
  url: https://www.candidrx.com/about/overview/
- type: TermsOfService
  url: https://www.candidrx.com/terms-of-use/
- type: Accessibility
  url: https://www.candidrx.com/accessibility-statement/
- type: BoardOfDirectors
  url: https://www.candidrx.com/about/board-of-directors/
- type: SecondaryMarket
  url: https://forgeglobal.com/candid-therapeutics_stock/
- type: ParentCompany
  url: https://www.ucb.com/
- type: LLMsTxt
  url: llms/candid-therapeutics-llms.txt
x-acquisition:
  acquirer: UCB
  acquirer_slug: ucb
  announced: '2026-05-03'
  completed: '2026-06-17'
  value_usd: 2200000000
  terms: $2.0B upfront plus up to $200M in milestones
  source: https://www.ucb.com/newsroom/press-releases/article/ucb-completes-acquisition-of-candid-therapeutics-strengthening-next-generation-immunology-pipeline
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1